Global Rabies Monoclonal Antibody Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Rabies Monoclonal Antibody Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Rabies virus (RABV), a single-stranded RNA virus of the genus Lyssavirus, family Rhabdoviridae, invades the central nervous system, causing acute and zoonotic natural foci disease worldwide. Rabies Monoclonal Antibody contains only antibodies against one or two epitopes, becoming one of the best options for post-exposure prophylaxis of rabies. Rabies Monoclonal Antibody has the advantages of high neutralizing activity, strong specificity to the corresponding target, easy standardized production, etc., and has broad application prospects.

Market Overview:

The latest research study on the global Rabies Monoclonal Antibody market finds that the global Rabies Monoclonal Antibody market reached a value of USD 149.08 million in 2022. It’s expected that the market will achieve USD 836.59 million by 2028, exhibiting a CAGR of 33.31% during the forecast period.

Rabies Monoclonal Antibody Industry Development Trends under COVID-19 Outbreak

From the perspective of production, for the Rabies Monoclonal Antibody industry, the epidemic has affected the production plans of companies in the Rabies Monoclonal Antibody industry. Due to the outbreak of COVID-19, there may be shortages in the supply of raw materials such as reagents and consumables. For example, due to the restrictions on domestic transportation and movement of people in many countries during the epidemic, and restrictions on imported goods, this has caused problems in the supply of raw materials. On the other hand, due to the impact of the new crown pneumonia epidemic, in order to prevent the further spread of the epidemic, the government issued travel restrictions and related isolation policies, which reduced the management efficiency of enterprises in the industry and affected the company's production plan. In addition, due to the restrictions of the epidemic, the product research and development activities of industry companies have also been affected by a series of reasons such as personnel interruption.

From a sales perspective, the outbreak may cause delays in the promotion and marketing strategy of Rabies Monoclonal Antibody products. In addition, from a downstream point of view, the COVID-19 epidemic has led to a reduction in the travel time of residents for outdoor activities, prolonged contact with animals at home, and an increased risk of rabies exposure. The demand for Rabies Monoclonal Antibody may increase.

Drivers

Rabies Monoclonal Antibody enables large-scale production
Rabies Monoclonal Antibody enables large-scale production Rabies Monoclonal Antibody has production advantages compared to Human Rabies Immune Globulin. In this case, Rabies Monoclonal Antibody can be produced using large-scale molecular techniques, without the use of animals for production, and with unlimited yields. In general, in the case of insufficient supply of Human Rabies Immune Globulin, Rabies Monoclonal Antibody is expected to replace and expand the market. Therefore, the large-scale production of Rabies Monoclonal Antibody is one of the driving factors driving the development of the industry.

Industry Limitations

Rabies Monoclonal Antibody has a long development cycle
The Rabies Monoclonal Antibody industry is a high-tech, high-risk, high-input industry. From research and development, clinical trials, trial production to final product market development and product promotion of new drugs, a large amount of capital, technology, and other resources are required to be invested in each link, and there are also high requirements for the comprehensive quality of R&D personnel such as technical level and experience accumulation. A new drug needs to go through five stages from research and development to marketing: compound research and development, preclinical testing, IND declaration, clinical phase I, II, and III trials, registration and marketing, and the drug can only be marketed after being approved. At present, India has two anti-rabies virus monoclonal antibody drugs approved for marketing, and China has one anti-rabies virus monoclonal antibody drug approved for marketing. Due to the long R&D cycle, high technology, and large capital of Rabies Monoclonal Antibody, there are not many approved products on the market, and most of the participants are in the R&D stage. The long R&D cycle of Rabies Monoclonal Antibody is one of the challenges faced by the industry.

Region Overview:

In 2022, the share of the Rabies Monoclonal Antibody market in India stood at 54.91%.

Company Overview:

Serum Institute of India is now one of the world's largest manufacturers of vaccines including polio, diphtheria, tetanus, pertussis, Hib, BCG, r-hepatitis B, measles, mumps, rubella etc. and pneumococcus and Covid-19 vaccine. Serum Institute of India is ranked as India's No. 1 biotechnology company, manufacturing highly specialized lifesaving biologicals like vaccines using cutting edge genetic and cell based technologies, antisera and other medical specialties.

Zydus is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies, including small molecule drugs, biologic therapeutics and vaccines. September 2019, Zydus to launch novel biologic for rabies, TwinrabTM. The blood derived RIGs are in limited supply, expensive and can lead to infections and adverse reactions due to varying purity. As TwinrabTM is cell culture derived, it offers high levels of purity including freedom from risk of infections as compared to the human serum derived products. TwinrabTM will be produced in bioreactors, making it easier to produce in large quantities.

Serum Institute of India is one of the major players operating in the Rabies Monoclonal Antibody market, holding a share of 33.38% in 2023.

Segmentation Overview:

Category II Exposure
According to the product, it is divided into different risk exposure levels. Minor wounds such as a superficial scratch or abrasion without bleeding would be Category II.
Category III Exposure
Single or multiple transdermal bites or scratches, contamination of mucous membrane or broken skin with saliva from animal licks, exposures due to direct contact with bats (severe exposure)

By type, Category III Exposure segment accounted for the largest share of market in 2022.

Application Overview:

Adult
Distinguish according to the applicable population. Refers to Rabies Monoclonal Antibody for the prevention of rabies in adults.
Children
Refers to Rabies Monoclonal Antibody for the prevention of rabies in children.

The market's largest segment by application is the segment Adult, with a market share of 71.06% in 2022.

Key Companies in the global Rabies Monoclonal Antibody market covered in Chapter 3:

Serum Institute of India
Synermore Biologics
NCPC
Zydus

In Chapter 4 and Chapter 14.2, on the basis of types, the Rabies Monoclonal Antibody market from 2018 to 2029 is primarily split into:

Category II Exposure
Category III Exposure

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Rabies Monoclonal Antibody market from 2018 to 2029 covers:

Adult
Children

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)